| Mrs Courtney Rose Threats, LICSW, AADC | |
|
3 Whispering Pines Ct, West Warwick, RI 02893-5586 | |
| (401) 854-8334 | |
| Not Available |
| Full Name | Mrs Courtney Rose Threats |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 3 Whispering Pines Ct, West Warwick, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295446243 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Courtney Rose Threats, LICSW, AADC 3 Whispering Pines Ct, West Warwick, RI 02893-5586 Ph: (401) 854-8334 | Mrs Courtney Rose Threats, LICSW, AADC 3 Whispering Pines Ct, West Warwick, RI 02893-5586 Ph: (401) 854-8334 |
News Archive
A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.
People who gain less protection from cancer by eating broccoli may be able to compensate for the difference in their genetic make-up by eating 'super broccoli', a variety with higher levels of the active plant chemical sulforaphane, or by eating larger portions.
Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition products, Contract Manufacturing, and FormuTech Nutrition, one of the fastest-growing Sports Nutrition companies in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire FormuTech.
Praying for patients undergoing heart procedures off-site or giving them bedside therapy involving music, imagery, and touch (MIT) does not measurably improve their clinical outcome, suggests a study published in this week's issue of The Lancet. However, the authors note that patients receiving MIT therapy did have a lower mortality rate at 6 months.
› Verified 2 days ago